Best Life Sciences Companies in Herzliya, Israel
The 61 best Life Sciences companies in Herzliya, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MValve Technologies.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Herzliya
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MValve Technologies Stealth startup focused on Mitral Regurgitation solutions | $215M | 128 mo ago | 13 | — | Acqui-Hired | 29 patents Transcatheter cardiac valve support structures, sealing and delivery systems for heart valve implants | — |
| 2 | Prilenia Developer of therapeutics for the treatment of neurogenerative diseases | $134M | 56 mo ago | 39 | Michael R Hayden Founder & CEO | Series B | — | — |
| 3 | Orasis Pharmaceuticals Developer of reformulated eye drops for the treatment of Presbyopia 32Funding top 24%Moat top 32%Product top 40%Talent top 41% All 11 signals ▾Fundingtop 24% Moattop 32% Producttop 40% Talenttop 41% Patentstop 47% Globalbottom 45% Techbottom 44% Innovationbottom 40% Growthbottom 40% Marketbottom 34% Newsbottom 21% Funding: Raised $111M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 31 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $111M | 20 mo ago | 24 | Elad Kedar CEO | Series D | 31 patents Formulating and delivering ophthalmic drugs for eye disease treatment. | 1 launch |
| 4 | BlueWind Medical Developer of neurostimulation device for the treatment of overactive bladder 50Patents top 39%Funding top 40%Innovation top 43%Tech top 46% All 9 signals ▾Patentstop 39% Fundingtop 40% Innovationtop 43% Techtop 46% Moattop 47% Markettop 50% Talentbottom 49% Globalbottom 40% Newsbottom 22% Patents: 73 patents matched (strict assignee match) · 23 filings since 2022 vs 38 in 2017-21 Funding: Raised $64.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $64M | 1 mo ago | 95 | Dan Lemaitre Chairman & CEO | Series B | 73 patents Wireless implantable neurostimulation devices and antenna designs for neuromodulation therapy. | 1 launch |
| 5 | Eloxx Pharmaceuticals Developer of small molecule drugs for genetic diseases caused by nonsense mutations | $38M | 51 mo ago | 15 | — | Acquired | 63 patents Scalable synthesis and therapeutic application of pseudo‑trisaccharide aminoglycoside antibiotics for genetic disorders | — |
| 6 | Valcare Medical Developer of minimally-invasive technologies for mitral regurgitation treatment and repair | $28M | 93 mo ago | 30 | Steve Sandweg Chief Executive Officer | Series B | — | — |
| 7 | Endospan Provider of stent graft endovascular solution for aortic aneurysms | $25M | 128 mo ago | 40 | — | Acquired | 227 patents Branched, fatigue-resistant aortic stent‑grafts for complex endovascular vascular repairs | — |
| 8 | PainReform Specialty pharmaceutical company that develops products for the treatment of pain 32Product top 24%Funding top 34%Growth top 35%Moat top 38% All 11 signals ▾Producttop 24% Fundingtop 34% Growthtop 35% Moattop 38% Newstop 43% Talentbottom 49% Innovationbottom 44% Techbottom 42% Patentsbottom 39% Globalbottom 35% Marketbottom 21% Product: 2 product launch events in 12 mo · 6 distinct product lines Funding: Raised $12.0M across 3 rounds · 3 rounds over 8 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $12M | 11 mo ago | 6 | Michael Mulholland Chief Executive Officer | Public | 22 patents Sustained-release depot formulations for local anesthetics and hydrophobic drugs | — |
| 9 | Neurolief Wearable device for neurological and neuropsychiatric disorders 27Patents top 36%Talent top 38%Innovation top 39%Funding top 46% All 10 signals ▾Patentstop 36% Talenttop 38% Innovationtop 39% Fundingtop 46% Producttop 47% Moattop 47% Globalbottom 35% Marketbottom 28% Techbottom 26% Newsbottom 22% Patents: 55 patents matched (strict assignee match) · 18 filings since 2022 vs 29 in 2017-21 Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $11M | 3 mo ago | — | Shmuel Shany Co-Founder | Series A | 55 patents Wearable transdermal neurostimulation headsets integrating biosensing for therapeutic monitoring | 1 job opening |
| 10 | SMT Research and Development Embolic protection device | $10M | 183 mo ago | — | Nikolaus Schweinert CTO & Founder | Deadpooled | — | — |
| 11 | Geneyx Provider of a clinical genetics data management platform for hospitals and genetic labs | $10M | 55 mo ago | 31 | — | Seed | — | — |
| 12 | Respinova Acoustic waves to reopen small airways | $7M | 40 mo ago | 5 | Hans Brocker Co-Founder | Deadpooled | 40 patents Inhaled drug delivery systems, especially pulsating inhalers for respiratory and cardiopulmonary therapies. | — |
| 13 | SpacePharma Provider of microgravity research solutions for researchers, institutes, and commercial companies | $5M | 107 mo ago | 13 | Martin Aebi Co-Founder | Series A | 4 patents Microfluidic on‑orbit drug synthesis and precise liquid/powder delivery systems | 1 launch |
| 14 | WideMed Web-based sleep monitoring platform for the diagnosis of sleep disorders | $5M | 259 mo ago | — | Bar-Lev Yaacov Owner & Ceo & Chairman Of The Board | Public | 44 patents Non-invasive monitoring and analysis of cardiac and respiratory signals via photoplethysmography | — |
| 15 | Circ MedTech Non-surgical medical device for male circumcision | $4M | 179 mo ago | 3 | Tzameret Fuerst Co-Founder | Deadpooled | 7 patents Mass circumcision surgical devices and support systems for high‑throughput male genital procedures | — |
| 16 | CoreBone Developer of a bioactive, coral-based bone graft material | $4M | 57 mo ago | 5 | — | Series A | 5 patents Bioactive coral-derived bone grafts for orthopedic defect repair | — |
| 17 | TACount Imaging-based microbiological testing technology | $2M | 181 mo ago | — | Isak Duenyas Founder | Deadpooled | — | — |
| 18 | QuLab Medical Developer of minimally-invasive continuous glucose monitoring system | $750K | 41 mo ago | 8 | Idan Tamir CEO | Funding Raised | 38 patents Electrochemical FET biosensors for point‑of‑care medical diagnostics | — |
| 19 | Savicell Metabolomics-based blood tests for early detection of cancer. | $224K | 34 mo ago | 7 | — | Seed | — | — |
| 20 | Neurosteer Developer of a wearable band and a cloud platform for monitoring brain signals | $115K | 90 mo ago | 13 | — | Funding Raised | 24 patents Integrated neurofeedback and hybrid invasive/noninvasive brain stimulation technologies | — |
| 21 | Breedit Provider of data recording and analysis platform for plant breeders | $111K | 121 mo ago | — | Oded Sagee Founder & CEO | Funding Raised | — | — |
Top 12 Life Sciences companies in Herzliya
#1
Series B · Herzliya, Tel Aviv · founded 2010 · 95 employees$64Mraised▾
Developer of neurostimulation device for the treatment of overactive bladder. The flagship product of the company is "Renova" a wireless device that delivers targeted electric stimulation to the nerve for the treatment of patients with an Overactive Bladder and associated symptoms of urinary urgency and frequency.
- May 2026Series B$47.8M
- May 2026Conventional Debt—
- May 2022Series B$64M
#2
Series A · Herzliya, Tel Aviv · founded 2012$11Mraised▾
Neurolief is focussed on developing a wearable platform technology for brain neuromodulation. It is developing a wearable device that enables the safe and effective treatment for neuro disorders such as migraine and depression without interfering with the patient's daily activities. As of September 2016, the device is in clinical development.
- Mar 2026Series A$6M
- Aug 2025Series A$5M
- 2015Seed—
#3
Series D · Herzliya, Tel Aviv · founded 2015 · 24 employees$111Mraised▾
Orasis Pharmaceuticals is developing reformulated eye drops for the treatment of Presbyopia. They are developing CSF-1 eye drops that assist in eliminating the use of eyeglasses. It is used as a topical solution directly to the eye which improves the elasticity of crystalline glasses. The candidate is in phase II clinical trials.
- Oct 2024Venture Debt$10M
- Oct 2024Series D$68M
- Sep 2020Series C$30M
- Jun 2018Series B$13M
#4
Public · Herzliya, Tel Aviv · founded 2007 · 6 employees$12Mraised▾
Painreform is a specialty pharmaceutical company that develops products for the treatment of pain. It is focused on reformulations of established pain drugs by applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patients convenience as well as faster return of motor function. Its lead product PRF-110 provides a prolonged action of the local analgesic agent ropivacaine, a generic local analgesic drug. The company has applied for 2 PCT applications on its platform technology and on its lead product
- Jul 2025Post IPO$600K
- Mar 2021Post IPO$6M
- Jul 2018Series A$12M
#5
Series B · Herzliya, Tel Aviv · founded 2018 · 39 employees$133.5Mraised▾
Developer of therapeutics for the treatment of neurogenerative diseases. It has developed its lead product Pridopidine, a sigma-1 receptor (S1R) agonist, for the treatment of multiple movement disorders and neurodegenerative diseases in adults and children. The compound is also shown to treat Huntington's disease (phase III), ALS, Parkinson’s disease levodopa-induced dyskinesia (PD-LID), and other conditions.
- Nov 2021Series B$43M
- Jun 2020Series A$62.5M
#6
Acqui-Hired · Herzliya, Tel Aviv · founded 2012 · 13 employees$215Mraised▾
MValve Technologies is an Israeli-Americal company focused on developing solutions for Mitral Regurgitation (MR). MR is an abnormal reversal of blood flow from the heart's left ventricle into the left atrium. The company's product is a docking system for transcatheter mitral valve repair which works in conjunction with Boston Scientific's Lotus Valve. MValve has been backed by Boston Scientific since 2012. The $15 M deal with Boston Scientific in 2014 included a $200 M buyout option. In Oct 2015, the company announced the first human implantation of its device in a patient in Germany. Lotus Valve System has not received FDA approval as of Oct, 2015. It is CE marked.
- Oct 2015Series C$200M
- Jul 2014Series A$15M
#7
Acquired · Herzliya, Tel Aviv · founded 2013 · 15 employees$38Mraised▾
Eloxx Pharmaceuticals is a developer of small molecule drugs for genetic diseases caused by nonsense mutations. It helps in treating genetic diseases caused by nonsense mutations including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta-thalassemia and Tay-Sachs Hurler syndrome. Based on the technology developed at Israel Institute of technology, it is building a pipeline of molecules that can induce ribosomal readthrough to overcome the nonsense mutations and allow production of a full-length functional protein and hold great therapeutic potential for the treatment of many genetic diseases.
- Mar 2022Grant (prize money)—
- Aug 2020Series C—
- Jun 2019Series C—
- Aug 2017Series C$8M
#8
Deadpooled · Herzliya, Tel Aviv · founded 2008 · 5 employees$6.8Mraised▾
Respinova is focussed on developing non-invasive solutions for the treatment of respiratory disorders. It has developed PulseHaler which delivers a non-invasive treatment to the small airways and generates acoustic pressure pulses that travel into the lung well into the airways to the blocked small airways, thereby creating multiple momentary dilating forces that help pry open the collapsed airways. The device is in the clinical development for the treatment of small airways disease in COPD patients.
- Feb 2023Grant (prize money)$52.9K
- Jul 2022Grant (prize money)$51.1K
- Mar 2021Grant (prize money)$1.1M
- Feb 2019Grant (prize money)$2.8M
#9
Series B · Herzliya, Tel Aviv · founded 2012 · 30 employees$28Mraised▾
Developer of minimally-invasive technologies for mitral regurgitation treatment and repair. The company focuses on a mitral valve treatment platform based on a D-shaped ring. This ring serves as a tool for mitral annulus repair. It also functions as a docking station for future technology. The company's management team includes experts in sales, finance, and cardiovascular devices.
- Sep 2018Series B$20M
- Jul 2012Series A$8M
#10
Seed · Herzliya, Tel Aviv · founded 2018 · 31 employees$10Mraised▾
Provider of a clinical genetics data management platform for hospitals and genetic labs. The company offers an AI-based solution for next-generation sequencing (NGS) data, customizable workflows, rapid phenotype-driven interpretation, and Integrations that can scale the process of FASTQ to clinical reports for hospital and commercial labs.
- Nov 2021Seed$10M
#11
Acquired · Herzliya, Tel Aviv · founded 2009 · 40 employees$25Mraised▾
EndoSpan is a VC backed pre-clinical stage medical device start-up developing an endovascular system for endovascular aortic aneurysm repair. The Nexus platform helps in optimizing the open-heart surgery to minimally invasive procedures by giving real-time insights on the aortic conditions. It has two stent graft systems - Horizon, and Nexus. Both products are in clinical development.
- Oct 2015Series C$10M
- Series B$15M
#12
Series A · Herzliya, Tel Aviv · founded 2012 · 5 employees$3.7Mraised▾
Developer of a bioactive, coral-based bone graft material. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals to produce a coral-based bone substitute material with high integration ability.
- Oct 2021Series A$3.7M
- Nov 2013Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
- Mitochondrion1→5
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
- Agriculture3→6
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.